Kura Oncology, Inc.

NASDAQ:KURA

Biotechnology

Healthcare
$7.34 +0.73%

+$0.07 today

Market cap
$674.39M
Beta
0.36
P/E (TTM)
-2.9
EPS (TTM)
-$3.32
52W Low $5.45High $12.49

Volume 2.46M

Average 1.66M

KURA Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Kura Oncology, Inc.NASDAQ: KURA

Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026

Other non-cash items dips below year-ago levels

Q1 FY2026 other non-cash items of $794K (cash outflow) fell 68.6% year over year, behind the +377.7% change in trailing-twelve-month other non-cash items. Sequentially, it fell 69.0% from the prior quarter. Over 3 fiscal years it compounded at -32.6% a year.

Context

  • Other non-cash items amounted to 0.8% of revenue in FY2025, down 22.7 pp from a year earlier.
  • Other non-cash items increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -68.6% toward the trailing-twelve-month pace of +377.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$794K-69.0% QoQ
Last fiscal yearDec 2025
$515K+104.1% YoY
LTMMar 2026
$17.56M+377.7% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-68.6%——
1 year+104.1%——
3-year CAGR-32.6%——
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
515K USD
Year-over-year change
+104.1%
4-year CAGR
+6.6%

Other Non-Cash Items vs competitors

How KURA compares with its peers on the latest reported figures

  • KURA's LTM Mar 2026 other non-cash items of $17.56M is the 6th largest of the 11 companies compared; the peer median is $2.18M.
  • Its year-over-year change of +377.7% is the 3rd highest of 11, against a peer median of +65.6%.
  • Other non-cash items amounts to 24.5% of revenue for KURA, versus a peer median of 26.8%.
KURA Competitors Peer median
Other Non-Cash Items for KURA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HCMHUTCHMED (China) LimitedLTM Jun 2025$497.11M +767.3%+330.1%82.5%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$44.56M +5663.9%—14.9%
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 2026$33.38M -13.8%+1171.4%—
NRIXNurix Therapeutics, Inc.LTM Aug 2026$22.91M +92.3%—3.3%
VSTMVerastem, Inc.LTM Mar 2026$19.18M +15.6%+439.6%38.7%
KURAKura Oncology, Inc.LTM Mar 2026$17.56M +377.7%-32.6%24.5%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$3.05M -74.9%+41.1%1.4%
TYRATyra Biosciences, Inc.LTM Mar 2026$1.32M -76.1%——
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$1.26M +181.6%——
CRDFCardiff Oncology, Inc.LTM Mar 2026$804K +38.9%—153.1%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$461K +107.1%-61.1%—
Peer median (excluding KURA) $2.18M+65.6%+330.1%26.8%

Competitors are the stored peer set for KURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(130.47M)(135.84M)(152.63M)(173.98M)(278.67M)
Depreciation & Amortization558K759K849K848K(7.46M)
Deferred Income Tax4.6M0000
Stock-Based Compensation23.58M26.32M28.08M33.9M37.11M
Change in Working Capital(3.22M)(2.98M)7.82M286.17M184.44M
Accounts Receivables0000(6.74M)
Inventory0000(413K)
Accounts Payables(2.52M)(802K)10.33M15.2M4.5M
Other Working Capital(706K)(2.18M)(2.51M)270.97M187.1M
Other Non-Cash Items399K1.68M(8.94M)(12.62M)515K
Operating Cash Flow(104.55M)(110.06M)(124.82M)134.32M(64.06M)
Capital Expenditures(1.15M)(626K)(168K)(472K)(6.64M)
Acquisitions (Net)125.69K(33.25K)000
Purchases of Investments(445.66M)(270.66M)(409.82M)(659.05M)(761.59M)
Sales of Investments319.97M303.91M425.55M557.93M755.13M
Other Investing Activities(125.69K)33.25K000
Investing Cash Flow(126.84M)32.63M15.56M(101.59M)(13.1M)
Debt Repayment(7.25M)10M000
Common Stock Issued4.43M24.72M93.58M145.81M1.79M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(611K)3.84M1.21M8.6M0
Financing Cash Flow(3.44M)38.57M94.78M154.42M1.79M
Effect of Forex Changes00000
Net Change in Cash(234.82M)(38.87M)(14.48M)187.14M(75.36M)
Free Cash Flow(105.7M)(110.69M)(124.99M)133.85M(70.7M)

Kura Oncology, Inc.

NASDAQ:KURA

Intrinsic Alpha fair value

Locked

Current Price

$7.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.